Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL CEO Brian McNamee On Being Australia’s Only Homegrown MNC: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Australia's only homegrown multinational company in the pharmaceutical sector, CSL is at the forefront of producing a novel A H1N1 influenza vaccine, having signed a $180 million contract with U.S. Dept of Health and Human Services to provide the vaccine antigen in bulk form. CSL is also the originator of Merck's HPV vaccine Gardasil. CEO Brian McNamee talked with PharmAsia News' Australia bureau about CSL's operations at home and abroad.

Related Content

UsernamePublicRestriction

Register

SC071841

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel